Genelux (GNLX) Q2 2025 earnings summary

Executive summary

• Focused on developing oncolytic viral immunotherapies for aggressive solid tumors, with Olvi-Vec as the lead candidate in late-stage clinical trials and advanced toward potential registration in platinum-resistant/refractory ovarian cancer, with topline Phase 3 data expected in H1 2026.

• Achieved FDA alignment on trial design, potentially supporting traditional approval without a confirmatory trial.

• Strengthened executive team with the appointment of a new General Counsel and Head of Business Development.

• No products approved for sale; operations centered on R&D, clinical trials, and manufacturing scale-up.

• Net loss of $14.9 million for the six months ended June 30, 2025, with an accumulated deficit of $266.3 million.

Financial highlights

• Cash, cash equivalents, and investments totaled $28.1 million as of June 30, 2025, expected to fund operations into Q3 2026.

• Revenue for the six months ended June 30, 2025, was $8,000, compared to $208,000 in the prior year period.

• Research and development expenses increased to $9.5 million from $8.4 million year-over-year, driven by higher clinical trial costs.

• General and administrative expenses rose to $3.0 million from $2.5 million year-over-year, mainly due to higher salaries and professional services.

• Net loss was $7.5 million for Q2 2025, or $0.20 per share, compared to $6.6 million or $0.22 per share in Q2 2024.

Outlook and guidance

• Existing cash and investments expected to fund operations for the next 12 months from the filing date and into Q3 2026.

• Substantial additional funding will be required to complete clinical development and commercialization.

• Topline data from the Phase 3 OnPrime trial in ovarian cancer expected in H1 2026.

• Interim results from SCLC and NSCLC trials anticipated in the second half of 2025.